| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/27/2006 | WO2006045799A3 Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions |
| 07/27/2006 | WO2006041922A3 Agents and methods for administration to the central nervous system |
| 07/27/2006 | WO2006034315A3 Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| 07/27/2006 | WO2006023750A3 Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 07/27/2006 | WO2005114206A3 Diagnostics and therapeutics for diseases associated with serotonin 5-ht5a receptor (5ht5a) |
| 07/27/2006 | US20060168672 B7-like molecules and uses thereof |
| 07/27/2006 | US20060168667 Minibrain homologous proteins involved in the regulation of energy homeostasis |
| 07/27/2006 | US20060167261 e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty |
| 07/27/2006 | US20060167251 CCR9 inhibitors and methods of use thereof |
| 07/27/2006 | US20060167098 Method for the treatment of diseases linked to an accumulation of triglycerides and cholesterol |
| 07/27/2006 | US20060167086 Medicinal composition |
| 07/27/2006 | US20060167053 e.g. 3-(6-ethanesulfonylpyridin-3-yloxy)-5-(2-hydroxy-1-methyl-ethoxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide; glucokinase activator; antidiabetic agent; obesity, insulin resistance |
| 07/27/2006 | US20060167052 Piperidine derivative, process for producing the same, and use |
| 07/27/2006 | US20060167049 Terphenly derivatives, preparation thereof, compositions containing same |
| 07/27/2006 | US20060167048 N-4-piperidinyl compounds as ccr5 modulators |
| 07/27/2006 | US20060167036 Receptor or non-receptor; 5,6,7,8,9,10-hexahydro-6,9-(epiminomethano) benzo[ alpha ][8]annulenes; anticarcinogenic, antidiabetic, antiproliferative agents; autoimmune and Crohn's diseases, acromegaly, aging resistance; coadminister tamoxifen, raloxifene, taxol, trastuzumab, tirofiban or a COX-2 inhibitor |
| 07/27/2006 | US20060167020 Pyrazolopyrimidines as kinase inhibitors |
| 07/27/2006 | US20060167007 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof |
| 07/27/2006 | US20060167003 Probucol derivatives |
| 07/27/2006 | US20060167001 Pyridazinone-derivatives as pde4 inhibitors |
| 07/27/2006 | US20060166999 Use of microsomal triglyceride transfer protein (MTP) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (PPTRL) |
| 07/27/2006 | US20060166988 Novel compounds |
| 07/27/2006 | US20060166978 Inhibitors of IkB kinase (I Kappa B Kinase); 1-acetyl-7-bromo- beta -carboline; antiinflammatory and anticarcinogenic agent; asthma, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, infections, and cardiac infarct |
| 07/27/2006 | US20060166961 Cell adhesion inhibitors |
| 07/27/2006 | US20060166940 Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases |
| 07/27/2006 | US20060166899 prevention or treatment of disease associated with hyperglycemia: diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity; e.g. 4-[(4-{3-[1-carbamoyl-1-(methyl)-ethylcarbamoyl]propyl}-2-methylphenyl)methyl]-3-( beta -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole |
| 07/27/2006 | US20060166889 Chimeric peptides that facilitate the transport of insulin across biological membranes that have a first domain having a specific translocation sequence and a second domain having at least a biologically active portion of an insulin polypeptide; treatment of diabetes |
| 07/27/2006 | US20060166866 Cell adhesion inhibitors |
| 07/27/2006 | US20060166274 G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same |
| 07/27/2006 | US20060166255 Methods of using 48149, a human Aminopeptidase family member |
| 07/27/2006 | US20060165815 Choline-silicic acid complex with osmolytes and divalent trace elements |
| 07/27/2006 | US20060165758 Blunting the postprandial glycemic response by instant feed containing proteins, fats, carbohydrates, neutral soluble dietary fiber (guar gum, pectin, locust bean gum, methylcellulose), and hydrolyzed starch; diabetes |
| 07/27/2006 | US20060165757 5-hydroxysapogenin derivatives with anti-dementia activity |
| 07/27/2006 | US20060165720 Drug product for diabetes |
| 07/27/2006 | US20060165695 Antibody against human insulin-like growth factor |
| 07/27/2006 | US20060165689 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7 |
| 07/27/2006 | US20060165672 Fatigue reducing agent |
| 07/27/2006 | US20060165671 Novel nutraceutical compositions comprising epigallocatechin gallate |
| 07/27/2006 | DE102005002662A1 Use of ascorbigen as an agent for the reduction of aging processes and for the treatment of e.g. prostate cancer and osteoporosis |
| 07/27/2006 | CA2595486A1 Use of sirtuin-activating compounds for treating flushing and drug induced weight gain |
| 07/27/2006 | CA2594487A1 5-aminoindole derivatives |
| 07/26/2006 | EP1683805A1 Novel inhibitor for advanced glycation endproduct formation and aldose reductase inhibitor |
| 07/26/2006 | EP1683798A1 Novel fused polycyclic compound having heterocycle and medicinal use thereof |
| 07/26/2006 | EP1682664A2 Methods for the production of apolipoproteins in transgenic plants |
| 07/26/2006 | EP1682550A1 Substituted naphthyridinone derivatives |
| 07/26/2006 | EP1682540A1 Azolidinecarbonitriles and their use as dpp-iv inhibitors |
| 07/26/2006 | EP1682535A1 Heteroaryl derivatives as ppar activators |
| 07/26/2006 | EP1682528A1 BENZO [b][1,4] DIOXEPINE DERIVATIVES |
| 07/26/2006 | EP1682509A1 Pyridine carboxylic acid derivatives as glucokinase modulators |
| 07/26/2006 | EP1682508A1 Phenyl derivatives as ppar agonists |
| 07/26/2006 | EP1682507A1 Benzannelated compounds as ppar activators |
| 07/26/2006 | EP1682499A1 4-biarylyl-1-phenylazetidin-2-ones |
| 07/26/2006 | EP1682153A2 Methods of modulating angiogenesis and cancer cell proliferation |
| 07/26/2006 | EP1682122A1 Combinations of at1-antagonists, amiloride or triamterine, and a diuretic |
| 07/26/2006 | EP1682117A1 2-azetidinones as anti-hypercholesterolemic agents |
| 07/26/2006 | EP1682114A2 Methods of lowering lipid levels in a mammal |
| 07/26/2006 | EP1682112A1 Use of sulfonamide compounds for the treatment of diabetes and/or obesity |
| 07/26/2006 | EP1682095A1 Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| 07/26/2006 | EP1513839B1 3-substituted quinuclidines and their use |
| 07/26/2006 | EP1481065B1 Method for detection of leptin receptor ligands |
| 07/26/2006 | EP1390543B1 New polynucleotides and polypeptides of the ifnalpha-17 gene |
| 07/26/2006 | EP1381686B1 Inactivation of genes of the mep pathway |
| 07/26/2006 | EP1349578B1 Medicinal association of a biguanine (metformin) and arginine |
| 07/26/2006 | EP1341532B1 Use of pyridoxamine for the treatment and inhibition of obesity-related complications |
| 07/26/2006 | EP1242067B1 Calcium formate as a dietary supplement |
| 07/26/2006 | EP1240313B1 Homologue enzymes of human heparanase and splice variants thereof |
| 07/26/2006 | EP1216025B1 Dispersion formulations containing lipase inhibitors |
| 07/26/2006 | EP1027069B1 Gene therapy for gaucher disease |
| 07/26/2006 | CN1809750A Acetyl-coenzyme A carboxylase 2 as a target in the regulation of fat and insulin action |
| 07/26/2006 | CN1809581A Alkylamino alkoxyl substituted C-glycosylisoflavones and preparing method and the use of the same |
| 07/26/2006 | CN1809570A [1,2,4 ]triazolo [1,5-a]pyrimidin-2-ylurea derivative and use thereof |
| 07/26/2006 | CN1809568A Pyrid (2, 1-a) - isoquinoline derivatives as dpp-iv inhibitors |
| 07/26/2006 | CN1809566A Cannabinoid receptor ligands and uses thereof |
| 07/26/2006 | CN1809565A Pyrrolodihydroisoquinolines as pde10 inhibitors |
| 07/26/2006 | CN1809564A Pyrrolodihydroisoquinolines as PDE10 inhibitors |
| 07/26/2006 | CN1809560A Thiazolylpiperidine derivatives as mtp inhibitors |
| 07/26/2006 | CN1809544A Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 07/26/2006 | CN1809541A Aniline derivatives |
| 07/26/2006 | CN1809529A Pharmaceutically useful salts of carboxylic acid derivates |
| 07/26/2006 | CN1809372A Melanocortin recptor 4(MC4) agonists and their uses |
| 07/26/2006 | CN1809369A Extract from plant of japanese parsley family and process for producing the same |
| 07/26/2006 | CN1809367A A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein |
| 07/26/2006 | CN1809285A Movement physiology improver |
| 07/26/2006 | CN1807426A Heteroaryl urea neuropeptide y y5 receptor antagonists |
| 07/26/2006 | CN1807417A Novel waterless crystallization-free rosuvastatin calcium |
| 07/26/2006 | CN1806845A Medicinal composition, its preparation process and quality control method |
| 07/26/2006 | CN1806796A Pharmaceutical composition containing valibose, its preparation method and application |
| 07/26/2006 | CN1266260C Purifying of crude polyunsaturated fatty acid oils |
| 07/26/2006 | CN1266151C Naphthyridine derivatives |
| 07/26/2006 | CN1266150C 1, 2-dihydro-2-oxo-1, 8-naphthyridine derivative |
| 07/26/2006 | CN1266129C New compounds having activity of lowing blood fat and cholesterol, their preparation method and pharmaceutical compositions containing them |
| 07/26/2006 | CN1266118C Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides |
| 07/26/2006 | CN1265836C Blood fat-lowering Chinese traditional medicine |
| 07/26/2006 | CN1265829C Healthy product for preventing and treating cardiovascular and cerebrovascular disease |
| 07/26/2006 | CN1265805C Chinese medicine oral preparation for lowering blood sugar and its preparation method |
| 07/26/2006 | CN1265797C Application of timosaponin A3 in preparation of medicine for treating No.2 type diabetes mellitus |
| 07/26/2006 | CN1265795C Serial compound iron/calcium nutritious element tonic and preparation method thereof |
| 07/26/2006 | CN1265792C Use of niacin alkyl ester containing alkyl chain with 8 to 22 carbon atom in preparation of medicine for increasing leptin |
| 07/25/2006 | US7081476 Tocopherol enriched compositions for reducing IL6 levels |
| 07/25/2006 | US7081473 Glucose dependent-insulinotropic polypeptide, or gastric inhibitory polypeptide (GIP) inhibitors; p-methylidene hydrizide phenols |